Latest insights into the anticancer activity of gold(III)-dithiocarbamato complexes

Luca Ronconi, Donatella Aldinucci, Q. Ping Dou, Dolores Fregona

Research output: Contribution to journalArticlepeer-review


In this review paper we aim at giving a detailed overview on our research work devoted to the design of gold-based anticancer agents. In particular, during the last decade, we have been developing some gold(III)-dithiocarbamato derivates showing outstanding in vitro and in vivo antitumor properties and reduced, or even no, systemic and renal toxicity, compared to the reference clinically-established anticancer drug cisplatin. Starting from the rationale behind our investigations, we here summarize the results achieved so far, focusing on the latest in-depth mechanistic studies that have recently provided insights into their mechanism of action, thus opening up new prospects for further pharmacological testing and, hopefully, to enter clinical trials.

Original languageEnglish
Pages (from-to)283-292
Number of pages10
JournalAnti-Cancer Agents in Medicinal Chemistry
Issue number4
Publication statusPublished - May 2010


  • Anticancer drug
  • Dithiocarbamate
  • Gold compounds
  • Metallodrug
  • Nephrotoxicity
  • Proteasome inhibitor
  • Reactive oxygen species (ROS)
  • Thioredoxin reductase (TrxR)

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Pharmacology


Dive into the research topics of 'Latest insights into the anticancer activity of gold(III)-dithiocarbamato complexes'. Together they form a unique fingerprint.

Cite this